Publicação
BREAST ANGIOSSARCOMA AFTER RADIOTHERAPY
| Resumo: | Breast angiosarcoma is a rare tumor that can be divided in 3 groups: primary, secondary to chronic lymphoedema and secondary to radiotherapy (RT). It has a poor prognosis and a bad response to surgery and chemotherapy (QT). A female patient was observed with a very indurated erythematous-violaceous plaque, with an ecchymotic halo that occupied the right breast, and was evolving for 8 months. The patient had history of breast cancer, treated with surgery (tumourectomy) and local RT 5 years before. The incisional biopsy showed a vascular proliferation, arranged in nodules but also with diffuse growing, with cytological atypia and strong expression of CD31, CD34 and factor VIII, consistent with post-RT angiosarcoma. The patient begun RT and QT, but had no significant clinical response. She is now waiting for approval to begin pazopanib. |
|---|---|
| Autores principais: | Ramos, Leonor |
| Outros Autores: | Simões, Pedro; Gouveia, Miguel; Pereira, Neide; Cardoso, José Carlos; Figueiredo, Américo |
| Assunto: | Breast neoplasms Hemangiosarcoma Radiotherapy Angiossarcoma Neoplasias da mama Radioterapia |
| Ano: | 2015 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Instituição associada: | Sociedade Portuguesa de Dermatologia e Venereologia |
| Idioma: | português |
| Origem: | Portuguese Journal of Dermatology |
| Resumo: | Breast angiosarcoma is a rare tumor that can be divided in 3 groups: primary, secondary to chronic lymphoedema and secondary to radiotherapy (RT). It has a poor prognosis and a bad response to surgery and chemotherapy (QT). A female patient was observed with a very indurated erythematous-violaceous plaque, with an ecchymotic halo that occupied the right breast, and was evolving for 8 months. The patient had history of breast cancer, treated with surgery (tumourectomy) and local RT 5 years before. The incisional biopsy showed a vascular proliferation, arranged in nodules but also with diffuse growing, with cytological atypia and strong expression of CD31, CD34 and factor VIII, consistent with post-RT angiosarcoma. The patient begun RT and QT, but had no significant clinical response. She is now waiting for approval to begin pazopanib. |
|---|